|Paul, Souren -|
|Kang, Sun Chul -|
Submitted to: New Biotechnology
Publication Type: Peer Reviewed Journal
Publication Acceptance Date: June 1, 2010
Publication Date: November 25, 2010
Citation: Paul, S., Hou, C.T., Kang, S. 2010. a-glucosidase inhibitory activities of 10-hydroxy-8(E)-octadecenoic acid, an intermediate of bioconversion of oleic acid to 7,10-dihydroxy-8(E)-octadecenoic acid. New Biotechnology. 27:417-423. Interpretive Summary: Previously, we discovered a new microbial culture Pseudomonas aeruginosa PR3 that produced 7,10-dihydroxy-fatty acid from oleic acid through an intermediate, 10-hydroxy-8(E)-octadecenoic acid (HOD). Hydroxy fatty acids are useful as starting materials for the synthesis of specialty chemicals, special military nylon, plastisizers, coating materials, and possible as physiologically active agents. Diabetes mellitus is a chronic disease caused by inherited or acquired deficiency in insulin secretion and by decreased responsiveness of the organs to secret insulin. a-Glucosidase inhibitors including acarbose and voglibose, are currently used clinically in combination with either diet or other anti-diabetic agents to control blood glucose levels of patients. Now we found that HOD has stronger anti - a-glucosidase activity than acarose. Our study is the first report on anti - a-glucosidase activity of HOD and could be helpful to develop medicinal preparation or functional food for diabetes and related symptoms.
Technical Abstract: Microbial conversion of unsaturated fatty acids often leads to special changes in their products structure and in biological potential. In our continuous effort to screen natural products for their anti-microbial and enzyme inhibitor activities, we found that 10-Hydroxy-8(E)-Octadecenoic acid (HOD) exhibited strong anti - a-glucosidase (EC 184.108.40.206) activity. HOD is an intermediate in the bioconversion of oleic acid to 7,10-dihydroxy-8(E)-Octadecenoic acid (DOD) by a bacterial isolate, Pseudomonas aeruginosa (PR3). Diabetes mellitus is the most serious, chronic metabolic disorder characterized by defect in insulin secretion and action, which can lead to damaged blood vessels and nerves. We analyzed the inhibitory activity of HOD and the commercially available anti-diabetic remedy, acarbose. We found that HOD exhibited a better inhibition (IC50 0.07 ±0.12) on a-glucosidase compared to acarbose (IC50 0.42 ± 0.1). HOD showed competitive inhibition against yeast a-glucosidase. Our study is the first report on anti - a-glucosidase activity of HOD and could be helpful to develop medicinal preparation or functional food for diabetes and related symptoms.